Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427128 · ClinicalTrials.gov registry record · Phase 4
Prozac Treatment of Major Depression: Discontinuation Study
A Phase 4 study of Major Depression, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 627
- Enrollment target
- 2
- Study locations
NCT00427128: Completed Phase 4 study of Major Depression, sponsored by New York State Psychiatric Institute.
NCT00427128 is a Phase 4 study of Major Depression that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 627 participants, above the 305-participant average among 28 other Major Depression trials with a reported enrollment target (106% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00427128, a Phase 4 study of Major Depression, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 627 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study randomized two stratifications of acute phase MDD SSRI responders, categorized as having either "true drug" response or "placebo response" pattern, to continuation with SSRI vs placebo in a double-blind trial to determine if stratification category predicted continuation outcome.
Conditions Studied
Interventions
- DRUG placebo
- DRUG fluoxetine
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 1995-11 |
| Est. Completion | 2003-03 |
| Phase | Phase 4 |
What the finished NCT00427128 record still lists
NCT00427128 is an interventional study that assigns participants to a tested intervention. The registered 627 participants enrollment target is mid-sized for trials with a published cap, above the 305-participant average among 28 other Major Depression trials with a reported enrollment target (106% higher).
The record links to 1 condition, with Major Depression appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00427128 reports a single indexed study location in Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00427128 about?
NCT00427128 is a clinical study titled "Prozac Treatment of Major Depression: Discontinuation Study". This study randomized two stratifications of acute phase MDD SSRI responders, categorized as having either "true drug" response or "placebo response" pattern, to continuation with SSRI vs placebo in a double-blind trial to determine if stratification category predicted continuation outcome.
What is the current status of trial NCT00427128?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 627 participants. The study started on 1995-11. Estimated completion is 2003-03.
What conditions does trial NCT00427128 study?
This clinical trial studies the following conditions: Major Depression.
What interventions are being tested in trial NCT00427128?
The interventions under investigation include: placebo (DRUG), fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00427128?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00427128 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00427128's enrollment target sits among peer trials
627 6th of 28 higher than 23 of 28 other Major Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.
COMPLETED · Phase 4
-
Preventing Depression Recurrence in Diabetes
COMPLETED · Phase 4
-
Pharmacotherapy in Depression With Panic Spectrum
COMPLETED · Phase 4
-
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
COMPLETED · Phase 4
-
Thyroid Medication and Antidepressants for Treating Major Depression
COMPLETED · Phase 4
-
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06040827 · 626 participants
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia